loading
Schlusskurs vom Vortag:
$9.26
Offen:
$10.46
24-Stunden-Volumen:
322.52K
Relative Volume:
8.46
Marktkapitalisierung:
$121.72M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.89M
KGV:
-13.36
EPS:
-0.7
Netto-Cashflow:
$-6.48M
1W Leistung:
-12.04%
1M Leistung:
-23.49%
6M Leistung:
-33.07%
1J Leistung:
-46.54%
1-Tages-Spanne:
Value
$9.25
$10.91
1-Wochen-Bereich:
Value
$9.06
$10.98
52-Wochen-Spanne:
Value
$9.06
$18.75

Greenwich Lifesciences Inc Stock (GLSI) Company Profile

Name
Firmenname
Greenwich Lifesciences Inc
Name
Telefon
203-434-3290
Name
Adresse
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Name
Mitarbeiter
0
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-08
Name
Neueste SEC-Einreichungen
Name
GLSI's Discussions on Twitter

Vergleichen Sie GLSI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
GLSI
Greenwich Lifesciences Inc
9.35 121.72M 0 -8.89M -6.48M -0.70
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-09-01 Eingeleitet H.C. Wainwright Buy

Greenwich Lifesciences Inc Aktie (GLSI) Neueste Nachrichten

pulisher
Apr 02, 2025

Flamingo cancer vaccine in phase III pink, Greenwich time nigh? - BioWorld MedTech

Apr 02, 2025
pulisher
Apr 02, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Apr 02, 2025
pulisher
Apr 02, 2025

Greenwich LifeSciences stock rises on cancer shot data (GLSI) - Seeking Alpha

Apr 02, 2025
pulisher
Apr 02, 2025

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Greenwich Lifesciences Announces Positive Immune Response Data From FLAMINGO-01 Phase III Clinical Trial - MarketScreener

Apr 02, 2025
pulisher
Apr 02, 2025

Clinical Trial Success: GLSI's Breast Cancer Therapy Shows Promising Results in Expanded Patient Group - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7%Time to Sell? - MarketBeat

Apr 02, 2025
pulisher
Apr 01, 2025

Recent 15% decline may not have gone down well with Greenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders who've been purchasing recently - simplywall.st

Apr 01, 2025
pulisher
Mar 31, 2025

Greenwich LifeSciences Delays Yearly Report Filing - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

How To Trade (GLSI) - news.stocktradersdaily.com

Mar 31, 2025
pulisher
Mar 27, 2025

Greenwich LifeSciences Extends Lock-Up Period for Directors, Officers to March 2026 - MarketScreener

Mar 27, 2025
pulisher
Mar 27, 2025

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026 - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Major Insider Confidence Signal: Greenwich LifeSciences Leadership Locks Shares Until 2026 - Stock Titan

Mar 27, 2025
pulisher
Mar 26, 2025

HER2-Positive Breast Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx, Alteogen - Barchart

Mar 26, 2025
pulisher
Mar 26, 2025

HER2-Positive Breast Cancer Pipeline 2025: Therapies, MOA - openPR.com

Mar 26, 2025
pulisher
Mar 25, 2025

GLSI stock touches 52-week low at $10.52 amid market challenges - Investing.com

Mar 25, 2025
pulisher
Mar 17, 2025

Greenwich LifeSciences gets DSMB approval to continue late-stage trial of GLSI-100 - MSN

Mar 17, 2025
pulisher
Mar 17, 2025

Greenwich LifeSciences Says Preliminary Safety Data for Breast Cancer Therapy Appears Consistent With Prior Trials - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Greenwich LifeSciences reports positive safety data on GLSI-100 - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01 - GlobeNewswire

Mar 17, 2025
pulisher
Mar 17, 2025

Greenwich's Breast Cancer Drug Proves Safe in Phase III Trial, Building on 80% Recurrence Reduction - StockTitan

Mar 17, 2025
pulisher
Mar 10, 2025

Trading (GLSI) With Integrated Risk Controls - news.stocktradersdaily.com

Mar 10, 2025
pulisher
Mar 05, 2025

Non-Small Cell Lung Cancer Clinical Trial Pipeline | 100+ Companies Pioneering the Future of Treatment - openPR

Mar 05, 2025
pulisher
Mar 05, 2025

55% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is owned by insiders, and they've been buying recently - Yahoo Finance

Mar 05, 2025
pulisher
Feb 27, 2025

Learn to Evaluate (GLSI) using the Charts - news.stocktradersdaily.com

Feb 27, 2025
pulisher
Feb 22, 2025

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Sees Large Increase in Short Interest - MarketBeat

Feb 22, 2025
pulisher
Feb 21, 2025

Short Interest in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Increases By 5.1% - MarketBeat

Feb 21, 2025
pulisher
Feb 20, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Verra Mobility Corporation (NASDAQ: VRRM) - PR Newswire

Feb 20, 2025
pulisher
Feb 18, 2025

Pre-market Movers: TNXP, INBS, SMMT, NDRA... - RTTNews

Feb 18, 2025
pulisher
Feb 18, 2025

Research Analysts Set Expectations for GLSI FY2024 Earnings - MarketBeat

Feb 18, 2025
pulisher
Feb 15, 2025

HC Wainwright Reiterates Buy Rating for Greenwich LifeSciences (NASDAQ:GLSI) - MarketBeat

Feb 15, 2025
pulisher
Feb 15, 2025

What is HC Wainwright’s Estimate for GLSI FY2024 Earnings? - Defense World

Feb 15, 2025
pulisher
Feb 12, 2025

Greenwich LifeSciences reports progress in FLAMINGO-01 trial - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

Greenwich LifeSciences (NASDAQ:GLSI) Given “Buy” Rating at HC Wainwright - Defense World

Feb 11, 2025
pulisher
Feb 11, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) - PR Newswire

Feb 11, 2025
pulisher
Feb 10, 2025

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01 - GlobeNewswire

Feb 10, 2025
pulisher
Feb 10, 2025

Greenwich LifeSciences reports progress in FLAMINGO-01 trial By Investing.com - Investing.com UK

Feb 10, 2025
pulisher
Feb 10, 2025

Clinical Trial Success: Greenwich's Breast Cancer Immunotherapy Achieves Critical Patient Milestone - StockTitan

Feb 10, 2025
pulisher
Feb 06, 2025

Greenwich LifeSciences: Long Time To Results, Little Cash, Hard To Recommend (GLSI) - Seeking Alpha

Feb 06, 2025
pulisher
Feb 06, 2025

(GLSI) Technical Pivots with Risk Controls - Stock Traders Daily

Feb 06, 2025
pulisher
Jan 30, 2025

EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial - Yahoo Finance

Jan 30, 2025
pulisher
Jan 29, 2025

Greenwich LifeSciences Gets EU Drug Regulator Approval to Add Sites to GLSI-100 Late-Stage Trial - Marketscreener.com

Jan 29, 2025
pulisher
Jan 29, 2025

Greenwich LifeSciences stock gains on approval to add additional sites to Flamingo-01 in Europe - MSN

Jan 29, 2025
pulisher
Jan 29, 2025

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe - GlobeNewswire

Jan 29, 2025
pulisher
Jan 29, 2025

Major Breakthrough: Cancer Prevention Trial Goes Europe-Wide as Top Medical Centers Join Forces - StockTitan

Jan 29, 2025
pulisher
Jan 28, 2025

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland - GlobeNewswire

Jan 28, 2025
pulisher
Jan 27, 2025

Greenwich LifeSciences Expands Phase III Breast Cancer Trial Across Poland - StockTitan

Jan 27, 2025
pulisher
Jan 26, 2025

How to Take Advantage of moves in (GLSI) - Stock Traders Daily

Jan 26, 2025

Finanzdaten der Greenwich Lifesciences Inc-Aktie (GLSI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Kapitalisierung:     |  Volumen (24h):